What question did this study set out to answer?

The study aims to evaluate the efficacy and safety of fluocinolone acetonide as baseline therapy in diabetic macular edema.

March 28, 2026Open Access

Fluocinolone Acetonide Implant as a Baseline Therapy for Diabetic Macular Edema: Results from the Randomized Phase 4 NEW DAY Study

Puntos clave

The study aims to evaluate the efficacy and safety of fluocinolone acetonide as baseline therapy in diabetic macular edema.
Conducted as a prospective, randomized study
Administered fluocinolone acetonide intravitreal implant (0.19 mg)
Evaluated participants with diabetic macular edema
Demonstrated efficacy in reducing macular edema
Showed acceptable safety profile for patients
Reports suggest positive outcomes as baseline therapy

Resumen

Purpose:The NEW DAY (NCT04469595) study assessed the efficacy and safety of the fluocinolone acetonide (FAc; 0.19 mg) intravitreal implant as baseline therapy in diabetic macular edema (DME).Design: Prospective, randomized, single-

Me gusta

Guardar

Ver artículo completo